Harrow Health Q2 Adj EPS $(0.02) Beats $(0.04) Estimate, Sales $33.47M Beat $31.04M Estimate
Portfolio Pulse from mahesh@benzinga.com
Harrow Health (NASDAQ:HROW) reported Q2 losses of $(0.02) per share, beating the analyst consensus estimate of $(0.04) by 50%. This is a 300% decrease over earnings of $0.01 per share from the same period last year. The company also reported quarterly sales of $33.47 million, beating the analyst consensus estimate of $31.04 million by 7.83%. This is a 43.51% increase over sales of $23.32 million the same period last year.
August 09, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Harrow Health's Q2 results beat analyst estimates for both EPS and sales. However, the company's EPS decreased by 300% compared to the same period last year.
While Harrow Health beat analyst estimates for both EPS and sales, the significant decrease in EPS compared to the same period last year could potentially concern investors. However, the strong sales growth could offset some of these concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100